[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

25

1 Jonas Salk, using an incomplete adjunct. We'll talk
2 briefly about the findings to date. Next slide.
3 So to summarize then, at least that we are
4 aware of data reported to date on three vaccine
5 products, again in seropositives, in seven clinical
6 trials; and, I emphasize, all are Phase I. Next
7 slide.
8 Now let's look at the highlights of the
9 clinical trials that have been reported to date. This
10 is not all of the clinical trials that have been done,
11 but this is what we have information on that has been
12 publicly reported.
13 There are four studies exclusively with
14 the MicroGeneSys gp-160: The first from the group at
15 Walter Reed; a second trial from the AIDS Clinical
16 Trial group; -- We'll be hearing about these two
17 studies in more depth -- a third study from the group
18 at the Paralinska; and finally, a group in Montreal at
19 McGill.
20 These are all relative small studies, they
21 being Phase I. Three of the four are open-label, one
22 a placebo control, all involving patients with mild to
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]